Fundraising FoxVenrock Healthcare Capital Partners — 2026 Investments
4 investments dated 2026 · listed companies and verified rows first · show all
Relmada is a clinical-stage biopharmaceutical company developing therapies including NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and Sepranolone, a candidate targeting compulsive behaviors via GABAA receptor modulation.
BiotechHealthtechNew York, US
Sergio Traversa(Executive Officer, Director)Paul Kelly(Director)Maged Shenouda(Director)inEliseo O. Salinas(President and Chief Scientific Officer)inDouglas Beck(Chief Financial Officer)Charles Ence(Chief Accounting and Compliance Officer)
Co-investorsBioAdvanceBAM ElevateBraidwellCommodore CapitalJanus Henderson InvestorsOrbiMed+2 more
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Carolyn Bertozzi(Lycia founder and Professor of Chemistry, Stanford University)inAetna Wun Trombley(President and CEO)inAmy Bachrodt(Chief Financial Officer)inChin Lee(Chief Medical Officer)inSteve Staben(Chief Scientific Officer)inSofia Touami(Chief Business Officer)in
Co-investorsREDMILEVersant VenturesHBM Healthcare InvestmentsHBM PartnersBAM ElevateFranklin Templeton+5 more
Mirador provides digital lending platform software for financial institutions, credit unions, and banks to streamline online loan applications.
Cloud ComputingEnterprise SoftwareFintechSaaS
Co-investorsCore Venture CapitalNycaNyca PartnersARCH Venture PartnersFidelity InvestmentsInvus+3 more
Mirador discovers and develops precision medicines for immune-mediated and immuno-fibrotic diseases using a target-patient matching approach.
AI & Machine LearningHealthtechMedical DevicesSan Diego, US
Mark C. McKenna(Founder, Chairman & CEO)inJoseph Papa(Director)Scott Glenn(Director)Vika Brough(Executive Officer)Timothy K. Andrews(Executive Officer)Mark McKenna(Founder)
Co-investorsAquiline Technology GrowthARCH Venture PartnersOrbiMedSanofi VenturesTruStage VenturesInvus+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.